<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02185092</url>
  </required_header>
  <id_info>
    <org_study_id>4258</org_study_id>
    <secondary_id>RSRCH032089</secondary_id>
    <nct_id>NCT02185092</nct_id>
  </id_info>
  <brief_title>Probiotic Use in Patients With Prior COPD Exacerbation</brief_title>
  <official_title>Probiotic Use in Patients With Prior COPD Exacerbation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Oklahoma</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Oklahoma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to examine the hypothesis test that probiotics will reduce the
      frequency of exacerbation in patients with COPD.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Lost funding
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>COPD exacerbations</measure>
    <time_frame>1 year</time_frame>
    <description>The primary end point will be the number of COPD exacerbations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic Use</measure>
    <time_frame>1 year</time_frame>
    <description>Decreased oral or IV antibiotic use</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Systemic Steroid Use</measure>
    <time_frame>1 year</time_frame>
    <description>Decreased systemic steroid use</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>COPD</condition>
  <condition>Obstructive Lung Disease</condition>
  <arm_group>
    <arm_group_label>Sugar Pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 pill orally daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactobacillus GG</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 pill (2 x 10x 9 CFU) daily orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lactobacillus GG</intervention_name>
    <description>probiotic supplement</description>
    <arm_group_label>Lactobacillus GG</arm_group_label>
    <other_name>Culturelle</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>placebo</description>
    <arm_group_label>Sugar Pill</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients admitted to OUMC or VAMC with a COPD exacerbation and pneumonia with
             underlying COPD will be eligible and screened.

          2. Patients seen in VA Chest Medicine clinic, OU Physicians clinic and Pulmonary fellows
             clinic at PPOB who have had a COPD exacerbation within the last year.

          3. Patients over age 18

          4. Patients who have a pulmonary function test (PFT) showing COPD within 1 year of
             enrollment in the study or if the treating physician plans to obtain PFT as part of
             the patient's care plan.

          5. Patients will be considered to have a diagnosis of COPD if they have a FEV1 of less
             than 80% of predicted and a FVC/FEV1 ratio of less than 0.70 (as defined by GOLD
             criteria).

        Exclusion Criteria:

          1. Patients with less than one year of life expectancy from a concomitant diagnosis

          2. Any GI motility disorders or previous bowel resection surgery (short gut syndrome)

          3. Any patients with decreased immune function or on medication that may decrease immune
             function (other than low dose steroid or steroid taper).

          4. Patients admitted within the last one year with a diagnosis of pancreatitis

          5. Patients unable to give consent will not be included in the study.

          6. Patients unable to sign consent

          7. Patients already on azithromycin daily for COPD exacerbations

          8. Patients under department of corrections custody.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen S Allen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>OUHSC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>OUHSC</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2014</study_first_posted>
  <last_update_submitted>May 19, 2017</last_update_submitted>
  <last_update_submitted_qc>May 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>exacerbations</keyword>
  <keyword>COPD</keyword>
  <keyword>pneumonia</keyword>
  <keyword>probiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

